Antisense Therapeutics Limited
ATHJFOTCHealthcare
$0.01
$-0.04(-76.00%)
Market Cap$19635001
P/E Ratio—
52W High$0.075
52W Low$0.01
Antisense Therapeutics Limited (ATHJF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ATHJF · earnings · updated Jun 8, 2026
Latest Earnings
Q3 FY2024Report Date: Aug 29, 2024EPS Actual
-$0.00
Est. -$0.00 · -15.3%
Revenue
$0.00B
Fiscal Period
Q3 FY2024
FY ends December
Report Date
Aug 29, 2024
After Market Close
▼ Miss EPS
ATHJF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2025 | Aug 27, 2025 | — | — | — | — | — | — |
| ◌ Q1 FY2025 | Feb 26, 2025 | — | — | — | — | — | — |
| ◌ Q4 FY2024 | Nov 14, 2024 | — | — | — | — | — | — |
| ▼ Q3 FY2024 | Aug 29, 2024 | -$0.00 | -$0.00 | -15.3% | $0.00B | — | — |
| ◌ Q2 FY2024 | Apr 29, 2024 | — | — | — | — | — | — |
| ▲ Q1 FY2024 | Feb 28, 2024 | -$0.01 | -$0.00 | +18.2% | $0.00B | — | — |
| ▲ Q2 FY2023 | Jun 30, 2023 | -$0.01 | -$0.01 | +39.3% | $0.00B | — | — |
| ▲ Q4 FY2022 | Dec 30, 2022 | -$0.01 | -$0.01 | +28.1% | $0.00B | — | — |
Q3 FY2025
Aug 27, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Feb 26, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 14, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Aug 29, 2024Miss
EPS Actual
-$0.00
EPS Est.
-$0.00
EPS Surpr.
-15.3%
Revenue
$0.00B
Q2 FY2024
Apr 29, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Feb 28, 2024Beat
EPS Actual
-$0.00
EPS Est.
-$0.01
EPS Surpr.
+18.2%
Revenue
$0.00B
Q2 FY2023
Jun 30, 2023Beat
EPS Actual
-$0.01
EPS Est.
-$0.01
EPS Surpr.
+39.3%
Revenue
$0.00B
Q4 FY2022
Dec 30, 2022Beat
EPS Actual
-$0.01
EPS Est.
-$0.01
EPS Surpr.
+28.1%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2024 | $-0.01 | $-0.01 | $-0.01 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q3 FY2024 | Aug 29, 2024 | -15.3% | $0.01 | $0.01 | +0.00% |
| ▲ Q1 FY2024 | Feb 28, 2024 | +18.2% | $0.05 | $0.03 | -50.00% |
| ▲ Q2 FY2023 | Jun 30, 2023 | +39.3% | $0.05 | $0.03 | -50.00% |
| ▲ Q4 FY2022 | Dec 30, 2022 | +28.1% | $0.07 | $0.07 | +0.00% |
| ▲ Q3 FY2022 | Aug 31, 2022 | +60.0% | $0.06 | $0.06 | +0.00% |
| — Q2 FY2022 | Jun 30, 2022 | — | $0.07 | $0.07 | +0.00% |
| ▲ Q4 FY2021 | Dec 30, 2021 | +64.3% | $0.15 | $0.15 | +0.00% |
| ▲ Q2 FY2021 | Jun 30, 2021 | +19.3% | $0.14 | $0.14 | +0.00% |
Q3 FY2024+0.00%
Report Date
Aug 29, 2024
EPS Beat/Miss
-15.3%
Price Before
$0.01
Price After
$0.01
Q1 FY2024-50.00%
Report Date
Feb 28, 2024
EPS Beat/Miss
+18.2%
Price Before
$0.05
Price After
$0.03
Q2 FY2023-50.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
+39.3%
Price Before
$0.05
Price After
$0.03
Q4 FY2022+0.00%
Report Date
Dec 30, 2022
EPS Beat/Miss
+28.1%
Price Before
$0.07
Price After
$0.07
Q3 FY2022+0.00%
Report Date
Aug 31, 2022
EPS Beat/Miss
+60.0%
Price Before
$0.06
Price After
$0.06
Q2 FY2022+0.00%
Report Date
Jun 30, 2022
EPS Beat/Miss
—
Price Before
$0.07
Price After
$0.07
Q4 FY2021+0.00%
Report Date
Dec 30, 2021
EPS Beat/Miss
+64.3%
Price Before
$0.15
Price After
$0.15
Q2 FY2021+0.00%
Report Date
Jun 30, 2021
EPS Beat/Miss
+19.3%
Price Before
$0.14
Price After
$0.14
Avg Beat Reaction-16.67%
Avg Miss Reaction+0.00%
Beat Rate6 / 8 quarters
Largest Move-50.00% (Q1 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ATHJF ends December
Antisense Therapeutics Limited (ATHJF) most recently reported earnings on August 29, 2024 for Q3 FY2024, posting EPS of $-0.00 — missing the analyst consensus of $-0.00 by -15.3%. The next ATHJF earnings date is expected around September 1, 2026.
Each quarter, investors track ATHJF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ATHJF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ATHJF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ATHJF earnings · 5 questionsAntisense Therapeutics Limited's next earnings report is expected around September 1, 2026. ATHJF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ATHJF historically reports after market close (AMC).
ATHJF earnings datewhen is ATHJF earningsATHJF next earnings datewhen does ATHJF report earningsATHJF earnings calendar
▸ Source: FMP · Antisense Therapeutics Limited SEC filings · US GAAP · Antisense Therapeutics Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026